Human Longevity, Inc. (HLI) has integrated the Avantect® test into its cancer prevention program, aiming to enhance early detection of pancreatic cancer among high-risk individuals. The Avantect test, developed by ClearNote Health, is a cell-free DNA-based blood test designed to identify early-stage pancreatic cancer.
According to MedTech Spectrum, the Avantect test demonstrated a sensitivity of 68.3% and a specificity of 96.9% for early-stage pancreatic cancer detection. These metrics suggest the test’s potential in identifying cancer at stages where intervention may be more effective.
HLI’s decision to incorporate the Avantect test reflects its commitment to integrating advanced diagnostic tools into its preventive health strategies. By offering this test, HLI aims to provide its clients with access to cutting-edge technologies that support early detection and intervention.
The integration of the Avantect test into HLI’s program underscores the company’s focus on leveraging innovative solutions to address complex health challenges. As part of its broader mission, HLI continues to explore and adopt technologies that contribute to proactive health management.
